Search Result

Isoforms Recommended:	MEK1

Results for "

MEK1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MEK (99) 5-HT Receptor (3) Akt (14) AP-1 (1) Apoptosis (41) Aryl Hydrocarbon Receptor (2) Autophagy (17) Bcl-2 Family (1) Beta-secretase (2) c-Met/HGFR (1) Calcium Channel (2) Casein Kinase (1) Caspase (5) CDK (3) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (2) COX (2) DNA/RNA Synthesis (1) Dopamine Receptor (3) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (1) Endogenous Metabolite (2) ERK (21) FLT3 (2) GLP Receptor (3) Glutathione S-transferase (1) GSK-3 (2) HDAC (1) IFNAR (1) Influenza Virus (2) Isotope-Labeled Compounds (5) JAK (3) JNK (5) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (2) Mitochondrial Metabolism (1) Mitophagy (3) MMP (3) Molecular Glues (1) NF-κB (4) NO Synthase (1) p38 MAPK (8) PARP (1) PD-1/PD-L1 (1) PDGFR (2) PDK-1 (1) PERK (6) PI3K (9) Pim (1) PKC (5) PROTACs (4) Raf (8) Ras (3) Reactive Oxygen Species (ROS) (8) Reference Standards (17) Small Interfering RNA (siRNA) (3) SOD (1) Src (1) STAT (1) TGF-beta/Smad (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1) Trk Receptor (3) VEGFR (4) β-catenin (1)
By Research Areas:	Cancer (107) Cardiovascular Disease (9) Infection (2) Inflammation/Immunology (22) Metabolic Disease (11) Neurological Disease (17)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

127

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: MEK ASK1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10999

Trametinib 285+ Cited Publications GSK1120212; JTP-74057	MEK Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis, cross the blood-brain barrier (BBB), used in research related to subarachnoid hemorrhage (SAH) ^[1] .

HY-10254

Mirdametinib 150+ Cited Publications PD0325901; PD325901	MEK Autophagy Apoptosis	Cancer
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive *MEK* inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i ^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts ^[1] .

HY-12031A

U0126 Maximum Cited Publications 459 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor ^[1] .

HY-50706

Selumetinib 85+ Cited Publications AZD6244; ARRY-142886	MEK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. Selumetinib can penetrate the blood brain barrier (BBB) ^[1] .

HY-13064

Cobimetinib 60+ Cited Publications GDC-0973; XL518	MEK Apoptosis	Cancer
Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-15202

Binimetinib 45+ Cited Publications MEK162; ARRY-162; ARRY-438162	MEK Autophagy	Cancer
Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-N0776

Isorhamnetin Maximum Cited Publications 17 Publications Verification 3'-Methylquercetin	MEK PI3K Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-12028

PD98059 390+ Cited Publications	MEK ERK Aryl Hydrocarbon Receptor Autophagy	Cancer
PD98059 is a potent and selective *MEK* inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of *MEK, thereby preventing the activation of MEK1* (IC₅₀ of 2-7 µM) and *MEK2* (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a *ERK1/2* signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy ^[1] .

HY-12031

U0126-EtOH Maximum Cited Publications 459 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor ^[1] .

HY-50295

CI-1040 20+ Cited Publications PD 184352	MEK Apoptosis	Cancer
CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of *MEK* with an IC₅₀ of 17 nM for MEK1.

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC₅₀=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) ^[1] .

HY-10999A

Trametinib (DMSO solvate) 285+ Cited Publications GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)	MEK Apoptosis	Cancer
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis ^[1] . This product is in solid form, a DMSO solvate, and a stable crystalline form.

HY-15610

GDC-0623 5+ Cited Publications RG 7421; MEK inhibitor 1	MEK Apoptosis	Cancer
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of *MEK1* (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAF ^V600E, EC₅₀=7 nM).

HY-12058

AZD8330 5+ Cited Publications ARRY-424704; ARRY-704	MEK	Cancer
AZD8330 (ARRY-424704) is a potent, uncompetitive *MEK1/MEK2* inhibitor, with an IC₅₀ of 7 nM.

HY-10542

GW 5074 5+ Cited Publications	Raf Apoptosis	Cancer
GW 5074 is a potent and selective c-Raf inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms ^[1] .

HY-P0119

Lixisenatide 2 Publications Verification	GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-13425

Deguelin 10+ Cited Publications (-)-Deguelin; (-)-cis-Deguelin	Akt Autophagy Apoptosis	Cancer
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-15196

TAK-285 3 Publications Verification	EGFR	Cancer
TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and *EGFR(HER1)* inhibitor with IC₅₀ of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for *HER1/2* than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity ^[1]. TAK-285 can cross the blood-brain barrier (BBB) .

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric *MEK1/MEK2* inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-50706A

Selumetinib sulfate 85+ Cited Publications AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Selumetinib (AZD6244) sulfate is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) sulfate inhibits ERK1/2 phosphorylation. Selumetinib sulfate can penetrate the blood brain barrier (BBB) ^[1] .

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-13064A

Cobimetinib hemifumarate 60+ Cited Publications GDC-0973 hemifumarate; XL-518 hemifumarate	MEK Apoptosis	Cancer
Cobimetinib hemifumarate is a novel selective *MEK1* inhibitor, and the IC₅₀ value against MEK1 is 4.2 nM.

HY-B0023

Azelnidipine 3 Publications Verification CS 905	Calcium Channel MEK	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting *MEK1/2*. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects ^[1] .

HY-153864

*PROTAC MEK1* Degrader-1**	PROTACs MEK ERK	Cancer
PROTAC MEK1 Degrader-1 is a PROTAC targeting *MEK1* with a pIC₅₀ value of 7.0. PROTAC MEK1 Degrader-1 consists of a *MEK1* inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit *ERK1/2* phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells ^[1].

HY-14719

RO4987655 5+ Cited Publications CH4987655	MEK	Cancer
RO4987655 is an orally active and highly selective *MEK* inhibitor with an IC₅₀ of 5.2 nM for inhibition of *MEK1/MEK2*.

HY-15437

SL327 5+ Cited Publications	MEK	Cancer
SL327 inhibits *MEK1* and *MEK2, with IC₅₀* values of 180 nM and 220 nM, respectively.

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive *MEK1/2* inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research ^[1].

HY-18086

TCS PIM-1 1 4 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive *Pim-1* kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) ^[1].

HY-100627

APS-2-79	MEK	Cancer
APS-2-79 is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling ^[1].

HY-130602

MS432	PROTACs MEK	Cancer
MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for *MEK1* and *MEK2. MS432 displays good plasma exposure in mice, exhibiting DC₅₀* values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively ^[1].

HY-156625

Nedometinib 1 Publications Verification NFX-179	MEK PERK p38 MAPK	Cancer
Nedometinib (NFX-179) is a specific *MEK1* inhibitor with an IC₅₀ of 135 nM. Nedometinib inhibits p-ERK, MAPK. Nedometinib exerts anticancer activity against squamous cell carcinoma. Nedometinib can be used for research in dermatosis, neurofibromatosis ^[1] .

HY-10999R

Trametinib (Standard) GSK1120212 (Standard); JTP-74057 (Standard)	Reference Standards MEK Autophagy Apoptosis	Cancer
Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 ^[1].

HY-10999S

Trametinib-d4	MEK Autophagy Apoptosis	Cancer
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GLP Receptor Akt MEK Reactive Oxygen Species (ROS) Apoptosis MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable ^[1].

HY-131295

PD0325901-O-C2-dioxolane 2 Publications Verification	MEK Ligands for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of *MEK* inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader ^[1].

HY-142042

3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles	MEK TGF-beta/Smad	Neurological Disease Inflammation/Immunology Cancer
3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC₅₀ of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model ^[1] .

HY-E70746

MEK1 SESE Recombinant Human Active Protein Kinase	MEK	Cancer
MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 SESE is a mutant of MEK1. MEK1 SESE Recombinant Human Active Protein Kinase is a recombinant MEK1 SESE protein that can be used to study MEK1 SESE-related functions ^[1].

HY-13064S1

Cobimetinib-d4 hydrochloride GDC-0973-d4hydrochloride; XL518-d4 hydrochloride	MEK Apoptosis Isotope-Labeled Compounds	Cancer
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

HY-115674

ML175	Glutathione S-transferase Akt MEK	Neurological Disease Inflammation/Immunology
ML175 is a specific glutathione transferase Omega 1-1 (GSTO1-1) inhibitor. ML175 can significantly activate Akt and *MEK1/2* kinases. ML175 can be used in the research of diseases such as Parkinson's disease ^[1].

HY-113592

ERK-IN-4 1 Publications Verification	ERK	Cancer
ERK-IN-4 is an ERK inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 ^[1].

HY-170982

MS910	MEK PROTACs	Cancer
MS910 is an efficient and selective MEK1/2 PROTAC degrader. MS910 exhibits effective MEK1/2 degradation ability and anti proliferative activity in various cancer cells, such as HT-29 (MEK1 DC₅₀ = 118 nM, MEK2 DC₅₀ = 55 nM) and SK-MEL-28 (MEK1 DC₅₀ = 94 nM, MEK2 DC₅₀ = 38 nM) cells. MS910 is commonly used in cancer research. (Pink: MEK1/2 Ligand (HY-10254); Blue: CRBN Ligand (HY-W087383); Black: Linker (HY-W022240)) ^[1]

HY-E70744

MEK1 F53L Recombinant Human Active Protein Kinase	MEK	Cancer
MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 F53L is a mutant of MEK1. MEK1 F53L Recombinant Human Active Protein Kinase is a recombinant MEK1 F53L protein that can be used to study MEK1 F53L-related functions ^[1].

HY-E70745

MEK1 P124L Recombinant Human Active Protein Kinase	MEK	Cancer
MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 P124L is a mutant of MEK1. MEK1 P124L Recombinant Human Active Protein Kinase is a recombinant MEK1 P124L protein that can be used to study MEK1 P124L-related functions ^[1].

HY-111033

RO5068760	MEK ERK Apoptosis p38 MAPK CDK PARP	Inflammation/Immunology Cancer
RO5068760 is a potent, orally active and selective non-ATP-competitive *MEK1/2* inhibitor with an IC₅₀ of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research ^[1].

HY-100627A

APS-2-79 hydrochloride	MEK	Cancer
APS-2-79 hydrochloride is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling ^[1].

HY-10999S1

Trametinib-13C6	MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

Cat. No.	Product Name	Target	Research Area

HY-P0119

Lixisenatide 2 Publications Verification	GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GLP Receptor Akt MEK Reactive Oxygen Species (ROS) Apoptosis MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable ^[1].

HY-P5977

*STE-MEK1(13)* Ste-MPKKKPTPIQLNP-NH₂; ERK Activation Inhibitor Peptide	ERK	Cancer
STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH ) is a cell permeable *ERK1/2* inhibitor (IC₅₀: 13-30 μM). STE-MEK1(13) inhibits ERK1/2 phosphorylation ^[1] .

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM ^[1] .

HY-P4136

*Myristoyl-MEK1* Derived Peptide Inhibitor 1**	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM ^[1].

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0776

Isorhamnetin Maximum Cited Publications 17 Publications Verification 3'-Methylquercetin	Cardiovascular Disease Flavonols Classification of Application Fields Hippophaë rhamnoides Plants Endogenous metabolite Flavonoids Microorganisms Leguminosae Elaeagnaceae Phenols Polyphenols Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	MEK PI3K Endogenous Metabolite
Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-13425

Deguelin 10+ Cited Publications (-)-Deguelin; (-)-cis-Deguelin	Flavonoids Classification of Application Fields Leguminosae Isoflavanones Derris trifoliata Lour. Plants Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	Akt Autophagy Apoptosis
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species (ROS)
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease ^[1]. Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0226

Epiberberine	Alkaloids Structural Classification Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease ^[1]. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N0392

Polygalasaponin F	Triterpenes Structural Classification Classification of Application Fields Terpenoids Polygalaceae Polygala japonica Houtt. Plants Inflammation/Immunology Disease Research Fields Source Classification	Toll-like Receptor (TLR) PI3K Akt NF-κB MDM-2/p53 Caspase MEK Bcl-2 Family p38 MAPK Mitophagy Reactive Oxygen Species (ROS) Apoptosis Calcium Channel
Polygalasaponin F is an orally active triterpenoid saponin monomer. Polygalasaponin F downregulates the expression of Bax, p53, caspase-3, NF-κB p65 and *MEK1; restores and upregulates the expression of Bcl-2; activates the PI3K/Akt* signaling pathway; inhibits the phosphorylation of p38 MAPK, nuclear translocation of NF-κB, TLR4-mediated signaling pathway, mitophagy (Mitophagy) and ROS production; enhances cell viability and suppresses apoptosis (Apoptosis). Polygalasaponin F maintains mitochondrial function, alleviates Ca ²⁺ overload, upregulates pCREB and BDNF, preserves cell viability and inhibits the release of inflammatory cytokines. Polygalasaponin F alleviates lung injury induced by influenza A *H1N1* and cerebral ischemia-reperfusion injury. Polygalasaponin F is applicable to researches related to Parkinson's disease, cerebral ischemia, pneumonia induced by influenza A *H1N1*, stroke and Alzheimer's disease ^[1] .

HY-N0909

Notoginsenoside R2 1 Publications Verification 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Neurological Disease Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the *MEK1/2-ERK1/2* pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ_25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis ^[1] .

HY-N12445

Quercetin-3'-O-glucoside 1 Publications Verification	Malvaceae Structural Classification Flavonols Flavonoids Abelmoschus manihot (Linn.) Medicus Plants Source Classification	Topoisomerase Caspase Apoptosis SOD
Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors ^[1] .

HY-107417

Hypothemycin	Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Phenols Disease Research Disease Research Fields Source Classification Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

HY-13425R

Deguelin (Standard) (-)-Deguelin (Standard); (-)-cis-Deguelin (Standard)	Structural Classification Flavonoids Leguminosae Isoflavanones Derris trifoliata Lour. Plants Source Classification	Akt Autophagy Apoptosis Reference Standards
Deguelin (Standard) is the analytical standard of Deguelin. This product is intended for research and analytical applications. Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-N0776R

Isorhamnetin (Standard) 3'-Methylquercetin (Standard)	Cardiovascular Disease Classification of Application Fields Hippophaë rhamnoides Plants Endogenous metabolite Flavonoids Leguminosae Elaeagnaceae Phenols Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	Reference Standards MEK PI3K Endogenous Metabolite
Isorhamnetin (Standard) is the analytical standard of Isorhamnetin. This product is intended for research and analytical applications. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-113632

Debromohymenialdisine 10Z-Debromohymenialdisine	Structural Classification Alkaloids Pyrrole Alkaloids Classification of Application Fields Marine natural products Sponge Disease Research Fields Cancer	Raf MEK
Debromohymenialdisine (10Z-Debromohymenialdisine) is a pyrrole alkaloid. Debromohymenialdisine has moderate inhibitory activity with an IC₅₀ value of 881 nM in the initial *Raf/MEK-1/MAPK* signaling cascade assay. Debromohymenialdisine can be used for the research of proliferation and differentiation ^[1].

HY-N0392R

Polygalasaponin F (Standard)	Triterpenes Structural Classification Terpenoids Polygalaceae Polygala japonica Houtt. Plants Source Classification	Reference Standards Toll-like Receptor (TLR) PI3K Akt NF-κB
Polygalasaponin F (Standard) is the analytical standard of Polygalasaponin F. This product is intended for research and analytical applications. Polygalasaponin F is an orally active triterpenoid saponin monomer. Polygalasaponin F downregulates the expression of Bax, p53, caspase-3, NF-κB p65 and *MEK1; restores and upregulates the expression of Bcl-2; activates the PI3K/Akt* signaling pathway; inhibits the phosphorylation of p38 MAPK, nuclear translocation of NF-κB, TLR4-mediated signaling pathway, mitophagy (Mitophagy) and ROS production; enhances cell viability and suppresses apoptosis (Apoptosis). Polygalasaponin F maintains mitochondrial function, alleviates Ca ²⁺ overload, upregulates pCREB and BDNF, preserves cell viability and inhibits the release of inflammatory cytokines. Polygalasaponin F alleviates lung injury induced by influenza A *H1N1* and cerebral ischemia-reperfusion injury. Polygalasaponin F is applicable to researches related to Parkinson's disease, cerebral ischemia, pneumonia induced by influenza A *H1N1*, stroke and Alzheimer's disease.

HY-N9980

Antcin K	Structural Classification Microorganisms Steroids Source Classification	PI3K Akt NF-κB p38 MAPK AP-1
Antcin K is a selective inhibitor targeting the PI3K/Akt, NF-κB, *MEK1/2-ERK, p38* and *AP-1* pathways. Antcin K upregulates IL-10 expression, thereby inhibiting the production of pro-inflammatory factors, blocking monocyte adhesion, reducing tissue damage, and promoting myogenesis. Antcin K has significant anti-inflammatory, anti-damage and tissue protective activities. Antcin K is mainly used in the research of inflammation-related diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury ^[1] .

Species:	Human (3) Mouse (1)
Tag:	His (2) GST (1) Flag (1)
Source:	Sf9 insect cells (4)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703585

	MEK1 Protein, Human (sf9, Flag) MEK1; PRKMK1	Human	Sf9 insect cells
	MEK1 Protein, Human (sf9, Flag) is the recombinant human-derived MAP2K1, expressed by sf9 insect cells , with Flag labeled tag.

HY-P703586

	MEK1 Protein, Human (Inactive, sf9, His) MEK1; PRKMK1	Human	Sf9 insect cells
	MEK1 Protein, Human (Inactive, sf9, His) is the recombinant human-derived MEK1, expressed by sf9 insect cells , with His labeled tag. ,

HY-P704011

	MEK1 Protein, Human (Active, Phosphorylated, sf9, His) MEK1; PRKMK1	Human	Sf9 insect cells
	MEK1 Protein, Human (Active, Phosphorylated, sf9, His) is the recombinant human-derived MEK1 protein, expressed by Sf9 insect cells, with N-6*His tag.

HY-P73825

	MEK1 Protein, Mouse (Inactive, sf9, His-GST) Dual specificity mitogen-activated protein kinase kinase 1; MAPKK 1; MEK 1; Map2k1	Mouse	Sf9 insect cells
	The MEK1 protein is a dual-specificity kinase that plays a crucial role in the MAP kinase pathway.MEK1 regulates various cellular processes such as growth, adhesion, survival, and differentiation, as well as transcription, metabolism, and cytoskeletal rearrangements.MEK1 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived MEK1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10999S

Trametinib-d4
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-13064S1

Cobimetinib-d4 hydrochloride
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-10999S1

Trametinib-13C6
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-10999S2

Trametinib-13C,d3
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-15202S3

Binimetinib-d4
Binimetinib-d₄ (MEK162-d₄) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-15202S1

Binimetinib-d3
Binimetinib-d₃ (MEK162-d₃) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM ^[1].

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

Host:	Mouse (1) Rabbit (12)
Reactivity:	Human (11) Rat (11) Mouse (12)
Application:	IHC-P (8) ICC/IF (9) IF-Tissue (2) IP (6) WB (13) FC (1) ELISA (3)
Isotype:	IgG (11) IgG/Kappa (1)
Conjugation:	Non-conjugated (13)
Clonality:	Monoclonal (8) Recombinant (4)
Modification:	Phosphorylated (3) Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80217

	MEK1 Antibody (YA300)	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	MEK1 Antibody (YA300) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MEK1.

HY-P86470

	MEK1 Antibody (YA6162) MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	MEK1 Antibody (YA6162) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MEK1.

HY-P86457

	MEK-1/2 Antibody (YA6149) MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1; MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein k	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	MEK-1/2 Antibody (YA6149) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MEK-1/2.

HY-P80832

	*Phospho-MEK1* (Ser298) Antibody (YA178)** 1 Publications Verification MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF	Human, Mouse, Rat
	Phospho-MEK1 (Ser298) Antibody (YA178) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MEK1 (Ser298).

HY-P80833

	*Phospho-MEK1* (Thr292) Antibody (YA177)** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB	Mouse, Rat
	Phospho-MEK1 (Thr292) Antibody (YA177) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MEK1 (Thr292).

HY-P810553

	*Phospho-MEK1* (Ser298) Antibody (YA9822)** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF, IF-Tissue, IHC-P	Human, Mouse, Rat
	Phospho-MEK1 (Ser298) Antibody (YA9822) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-MEK1 (Ser298).

HY-P810554

	*Phospho-MEK1* (Thr292) Antibody (YA9823)** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, IHC-P	Human, Mouse, Rat
	Phospho-MEK1 (Thr292) Antibody (YA9823) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-MEK1 (Thr292).

HY-P80832A

	*Phospho-MEK1* (Ser298) Antibody (YA178)(PBS only)** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF	Human, Mouse, Rat
	Phospho-MEK1 (Ser298) Antibody (YA178) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MEK1 (Ser298).

HY-P80833A

	*Phospho-MEK1* (Thr292) Antibody (YA177)(PBS only)** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB	Mouse, Rat
	Phospho-MEK1 (Thr292) Antibody (YA177) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MEK1 (Thr292).

HY-P810552

	*Phospho-MEK1/2 (Ser218 + S222) Antibody (YA9821)* MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF, IF-Tissue, IHC-P, IP	Human, Mouse, Rat
	Phospho-MEK1/2 (Ser218 + S222) Antibody (YA9821) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-MEK1/2 (Ser218 + S222).

HY-P85516

	MEK1 Antibody (YA5208) AA589381; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 1; ERK activator kinase 2; FLJ26075; MAP kinase kinase 1; MAP kinase kinase 2; MAP2K1; MAP2K2; MAPK/ERK kinase 1; MAPK/ERK kinase 2; MAPKK 1; MAPKK1; MAPKK2; MEK 1; MEKK1; Mitogen activated protein kinase kinase 1; Mitogen activated protein kinase kinase 2; Mitogen-activated protein kinase kinase 2, p45; MK2; MKK 1; MKK 2; MKK1; MKK2; MP2K1_HUMAN; PRKMK 1; PRKMK 2; Prkmk1; Prkmk2; protein kinase, mitogen-activated, kinase 1; MAP kinase kinase 1; Protein kinase, mitogen-activated, kinase 1; Protein kinase, mitogen-activated, kinase 2.	WB	Human
	MEK1 Antibody (YA5208) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to MEK1.

HY-P80218

	MEK1/2 Antibody (YA299) 1 Publications Verification	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	MEK1/2 Antibody (YA299) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MEK1/2.

HY-P86143

	*Phospho-MEK1/2(Ser217/221) Antibody (YA5835)*	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-MEK1/2(Ser217/221) Antibody (YA5835) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MEK1/2(Ser217/221).